IGI Logo

Indoco Remedies is currently trading at Rs. 380.05, up by 1.10 points or 0.29% from its previous closing of Rs. 378.95 on the BSE.

The scrip opened at Rs. 382.70 and has touched a high and low of Rs. 382.95 and Rs. 379.65 respectively. So far 426 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 416.95 on 01-Jan-2024 and a 52 week low of Rs. 307.00 on 26-Apr-2023.

Last one week high and low of the scrip stood at Rs. 404.00 and Rs. 370.25 respectively. The current market cap of the company is Rs. 3492.04 crore.

The promoters holding in the company stood at 58.74%, while Institutions and Non-Institutions held 19.37% and 21.88% respectively.

Indoco Remedies has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the Pre-Approval Inspection (PAI) conducted for the oral dosage form at the manufacturing facility located at Goa Plant-I, L-14 Verna Industrial Area Verna, Goa, India, in October 2023. The Company had addressed the observations comprehensively and within the stipulated time. The receipt of the Establishment Inspection Report indicates a successful closure of the inspection. The PAI was conducted for two drug product applications (ANDAs) filed from this facility, for which approvals are expected soon.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.